Related Experiment Video
Updated: Mar 29, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
35.0K
The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
Naazish S Bashir1,1, Wendy J Ungar1,1
1Child Health Evaluation Sciences, The Hospital for Sick Children Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, ON M5G 0A4, Canada.
Genome
|December 2, 2015
Summary
The 3-I framework helps analyze pharmacogenomics (PGx) policy gaps in Canada. This study identifies key challenges like genetic discrimination and consent to guide PGx testing implementation.
Area of Science:
- Genomics Policy
- Health Services Research
Background:
- Pharmacogenomics (PGx) testing lacks comprehensive policy in Canada compared to other nations.
- Effective policy development is crucial for integrating PGx into clinical practice.
Purpose of the Study:
- To apply the 3-I framework to pharmacogenomics (PGx) testing in Canada.
- To identify policy limitations and challenges for widespread PGx clinical adoption.
Main Methods:
- A scoping review of federal and provincial policies on PGx testing in Canada.
- Analysis using the 3-I framework (Ideas, Interests, Institutions).
Main Results:
- Key contentious ideas identified: genetic discrimination, informed consent, knowledge gaps, testing value, healthcare worker roles, and privacy.
- The 3-I framework revealed limitations in current Canadian PGx policy.
Conclusions:
- The 3-I framework is a valuable tool for Canadian genomics policy development.
- This analysis provides a foundation for creating targeted PGx policies at all governmental levels.
Keywords:
3-I frameworkcadre d’analyse des 3-Igenetic testinghealth policypharmacogeneticspharmacogenomicspharmacogénomiquepharmacogénétiquepolitique en matière de santétests génétiquesMore Related Videos
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
144
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
144
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:27Pharmacogenetics of Drug Metabolism: Overview
112
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
112
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:27Principles of Pharmacogenetics: Types of Genetic Variants
95
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
158
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
158